Regeneron Ending Eylea, Nesvacumab Combo Program

December 1, 2017: By Jon Swedien

Regeneron is ending the Eylea and nesvacumab combination program it had been developing with Bayer AG, the Tarrytown, New York, company announced Nov. 27.

Results from two Phase II studies that added the angiopoietin2 (Ang2) antibody nesvacumab to an Eylea (aflibercept) injection did not provide sufficient differentiation from Eylea monotherapy to warrant Phase III development, Regeneron said.

The RUBY study evaluated patients with diabetic macular edema (DME), and the ONYX study evaluated patients with wet age-related macular degeneration (wet AMD).

The randomized, double-masked studies evaluated two doses of nesvacumab in combination with aflibercept, both administered as a single co-formulated intravitreal injection, as well as aflibercept monotherapy. The primary endpoint for both trials was change in best-corrected visual acuity between week 12 and 36 as measured by the Early Treatment Diabetic Retinopathy Study letter score.

Eylea results were consistent with findings in previous clinical studies, and there were no new safety signals in these studies, Regeneron said.

The combination of aflibercept and nesvacumab was being jointly developed by Regeneron and Bayer AG under a global collaboration agreement. Regeneron maintains exclusive rights to Eylea in the US, and Bayer has licensed the exclusive marketing rights outside the US, where the companies share equally the profits from sales of Eylea, except for Japan where Regeneron receives a percentage of net sales.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Refocus Completes PMA Application for VisAbility as Treatment for Presbyopia

Novaliq’s NovaTears+Omega-3 Approved in Europe for Dry Eye

CooperVision Acquires Paragon Vision Sciences for $80 Million

AYOXXA Biosystems Launches Test for Biomarkers in Retinal Disease

Glaukos Announces New Patent for Glaucoma Stent Implanted in Schlemm’s Canal

Fortress Biotech Forms Tamid Bio Subsidiary; Lead Candidate is Ophthalmic Gene Therapy for MPS I

Samsung Launches App that Adjusts QLED TV Settings for Color-blind Viewers

Solar Eclipse Burns Crescent Wound in Woman’s Unprotected Retina

US Judge Refuses to Dismiss Allergan Suit against Imprimis

BioLight Sells IOPtima to Chengdu Kanghong Pharmaceutical Group for $56 Million

Regeneron Ending Eylea, Nesvacumab Combo Program

UK Retinal Drugmaker Exonate Forms Clinical Advisory Board

US FDA Approves RxSight’s Light Adjustable Lens and Light Delivery Device

EMA to Move to Amsterdam due to Brexit

First Subject Dosed in Nevakar’s Phase III Trial of NVK-002 for Myopia in Children

ProQR Doses First Patient in Phase I/II Trial for Leber’s Congenital Amaurosis 10

Aston EyeTech Raises $6.6 Million in Series A Equity Round

Ellex Raises $17.7 Million in Private Placement

Genentech’s Lampalizumab Fails Second Phase III Study in Geographic Atrophy

Judge Declares Mistrial in Corruption Trial of Melgen, Menendez

Coming soon

2017 Dry Eye Products Report: A Global Market Analysis for 2016 to 2022